Food and Drug Administration

CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE

October 11, 2001

Diovan (valsartan)

Slides

The files found on this pages are in a Portable Document Format (PDF) and are indicated by PDF to the right of the document. PDF Reader is a free download which enables viewing and printing of PDF format.

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Introduction, Mathias Hukkelhoven, PhD, Novartis Pharmaceuticals Corporation   pdf

Clinical Efficacy, Jay N. Cohn, MD, University of Minnesota Medical School   pdf

Efficacy Subgroup Analyses, Jay N. Cohn, MD, University of Minnesota Medical School   pdf

Diovan (valsartan) Safety, Robert Glazer, MD, Novartis Pharmaceuticals Corporation   pdf

Benefit: Risk Assessment, Jay N. Cohn, MD, University of Minnesota Medical School    pdf

Supporting Slides   pdf